NCT05527106

Evaluation of the Effect of Citicoline and Docosahexaenoic Acid (DHA) on the Visual Function of Patients With Glaucoma

Evaluation of the Effect of Citicoline (Cebrolux 800 mg) and Docosahexaenoic Acid (DHA) Compound (BrudyPio 1.5 g) on the Visual Function of Patients With Glaucoma With a Pilot Study

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 73 (actual)
• Sponsor: Institut Catala de Retina · Academic / Other
• Sex: All
• Age: 50 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

Pilot, single-blind, randomized and controlled study to evaluate the changes produced in the visual function of patients with glaucoma after oral administration for 3 months of citicoline and docosahexaenoic Acid (DHA) vs citicoline and docosahexaenoic Acid (DHA) vs vitamin C.

Conditions

• Glaucoma

Interventions

Type	Name	Description
DIETARY_SUPPLEMENT	Citicoline	Every subject randomized into this group have to take 2 sachets of Cebrolux 800 (362 mg of citicoline per day), every day, for 3 months.
DIETARY_SUPPLEMENT	Docosahexaenoic Acid (DHA)	Every subject randomized into this group have to take 3 pills of Brudypio 1.5g (1050 mg of DHA per day), every day, for 3 months.
DIETARY_SUPPLEMENT	Citicoline and Docosahexaenoic Acid (DHA)	Every subject randomized into this group have to take 2 sachets of Cebrolux 800 and 3 pills of Brudypio 1.5g per day, every day, for 3 months.
DIETARY_SUPPLEMENT	Vitamin C	Every subject randomized into this group have to take 1 pills of Vitamin C (500 mg per day), every day, for 3 months.

Timeline

• Start date: 2015-03-12
• Primary completion: 2022-05-25
• Completion: 2022-05-25
• First posted: 2022-09-02
• Last updated: 2022-09-02

Locations

1 site across 1 country: Spain